Publication | Closed Access

A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)

MedicinePathologyPhase Ii StudyBronchial NeoplasmFirst-line TreatmentCancer TreatmentOncologyRadiation OncologyLung CancerCancer Growth